Open Clinical Trials

The DFP study aims to create a database of different measures taken by people at risk of Alzheimer’s disease. The measures include regular brain scans, cognitive and memory tests, scans of magnetic fields generated by the brain, retinal imaging, blood tests, and the use of wearable technology to measure movement, gait, and ongoing cognitive abilities. In the future, the data obtained through DFP will help to understand if early interventions are working. (Closed to Recruitment)

The ISAP Study led in collaboration between the Diabetes Trial Unit and the Department of Psychiatry at the University of Oxford and Novo Nordisk will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer’s dementia. The trial will aim to recruit 88 volunteers currently living without dementia from five clinical sites in the UK: Oxford, Imperial College London, University College London, Exeter, and Bristol. Participants will have a PET head scan to check levels of amyloid protein in their brains. This new study is at the forefront of research that tests the concept that the long ‘preclinical’ stafe of dementia, that is, the 10-20 years period during which the condition develops, but people do not have symptoms, it is a window of opportunity to interfere with the disease process and delay or even prevent dementia.

Trial participants who have high amyloid protein levels in their brains will have further PET head scans to determine levels of protein. These scans will also check for tau protein, which is thought to damage nerves and to estimate levels of inflammation in the brain.

The ABATE trial is studying the effects of a study vaccine named ACI-24.060 in people with early Alzheimer’s disease. A build-up of protein Abeta (Aβ) in the brain is believed to play an important role in cognitive decline in Alzheimer’s disease. ACI-24.060 is designed to help reduce the quantity of Aβ in the brain and may thereby have a positive effect on cognitive decline.

Part II of the ABATE Study explores the effect of a new vaccine called ACI-24.060 on people with Down’s syndrome. People with Down’s syndrome have an increased risk of developing Alzheimer’s Disease. Alzheimer’s disease is caused by an increased level of ABeta (Aβ) protein leading to slowing down the cognitive abilities. The vaccine is designed to stimulate the immune system to produce antibodies against a build-up of the protein Abeta (Aβ) in the brain.

The Oxford Brain Heath Clinic (BHC) is a new integrated research and clinical environment. It is dedicated to preparing clinical services for the 21st century to preserve brain health. The clinic was launched in August 2020, as a pilot, to improve the assessment and diagnosis of memory problems. At the clinic, patients are given high-quality assessments not usually available in routine NHS care and are also offered the opportunity to take part in related research. https://oxfordhealthbrc.nihr.ac.uk/oxford-brain-health-clinic/

Alzheimer’s disease begins long before symptoms show. The ReTain study is evaluating whether an investigational medication is safe, tolerable and effective at slowing the onset of Alzheimer’s disease symptoms for those who may be at risk.

The WN45447 study aims to determine if an experimental drug can help slow down Alzheimer’s disease. WN45447 will include approximately 800 adults who have a recent diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease. Mild cognitive impairment means having problems with memory and thinking skills that are unlike usual age-related changes. (Open for Recruitment)

This trail is testing an investigational medication in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational medication and how well it may work to slow the progression of Alzheimer’s disease

The CVHB937A12201 Study is looking to find out more about an investigational medication (called a study drug) in people with mild AD. We want to look at the study drug to see if it has an effect on a person’s ability to think and remember, and causes serious side effects.

To do this, the study will compare the effects of 2 different doses of the study drug with a placebo. If you take part, you will receive either the study drug or placebo. A placebo is a ‘dummy medication’ that does not contain any active medication. You will also have the opportunity to take part in a study extension period, in which all participants will receive the study drug.

We are currently recruiting for the DNA, Children + Young People’s Health Resource (D-CYPHR), a study open to families with children aged 0 to 15 years. Most diseases start in childhood, but most health research is carried out in adults. D-CYPHR wants to change this by getting young people involved in research to help create better care for children and the adults they will become. We welcome all young people, with or without health conditions, to be part of D-CYPHR.

To find out more visit D-CYPHR | DNA, Children + Young People’s Health Resource

The Genetic Links to Anxiety and Depression (GLAD) Study is a project set up to support studies exploring risk factors for depression and/or anxiety. We are looking for people with lived experience of anxiety or depression and those who have never experienced any mental health disorder. By studying the differences between these two groups of people, we hope to improve understanding of how and why people develop anxiety and depression. By joining GLAD, you also become part of the NIHR BioResource.

We’re excited to be leading the SMILE BioResource, launching late 2025, in collaboration with the University of Oxford. The SMILE BioResource will support vital research into the causes, diagnosis, and treatment of severe mental illness.

Many people who receive antidepressant treatment for their depression do not get an adequate response to these treatments. This sometimes refer to as treatment-resistant depression or TRD. This study will explore whether an investigational medicine, COMP360 together with psychological support is an effective treatment for people who have not been helped by prior treatment for their depression.

There are currently limited treatment options available for people experiencing depressive symptoms. Very little is known about using antidepressants in patients living with bipolar. Antidepressants can be very effective in people with depression and can also be prescribed by a GP. In this study, we will use a combination of an antidepressant (sertraline) and an antipsychotic drug (aripriprazole) and compare this with a drug called quetiapine. Quetiapine is a common treatment for people experiencing depression in bipolar. All three drugs are already used in the NHS, but we want to find out if using a sertraline/aripiprazole combination will be beneficial in reducing depressive symptoms in people with bipolar.

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis.

This is a multi-center, randomized, double-blind, placebo-controlled, inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117570 in adults with a primary diagnosis of schizophrenia who are experiencing a worsening or relapse of symptoms.

The goal of the study is to see how well NBI-1117570 works, how safe it is, and how well it is tolerated compared to the placebo. Participants in this study have a 50:50 chance of receiving NBI-1117570 or placebo and will be randomly assigned to take 1 study medicine or the other. The expected duration of study participation for each participant is approximately 9 weeks.

This study aims to understand if a smartphone app can be used to collect information about memory and cognitive health. During the study, people with and without mental and neurological conditions will be asked, after providing informed consent, to download an app on their smartphone and complete daily assessments for 30 days.

We will collect information about how frequently they use the app as well as how satisfied they are about it. We will use the result of this study to inform the plan for a bigger research study that will look at find differences in the memory, reasoning and thinking of people with and without mental health or neurological conditions.